[1]HOSSEINKHANI N,DERAKHSHANI A,KOOSHKAKI O,et al.Immune checkpoints and CAR-T cells:the pioneers in future cancer therapies［J］.International Journal of Molecular Sciences,2020,21(21):8305.
[2]BURSHTYN DN,YANG W,YI T,et al.A novel phosphotyrosine motif with a critical amino acid at position-2 for the SH2 domain-mediated activation of the tyrosine phosphatase SHP-1［J］.J Biol Chem,1997,272(20):13066-13072.
[3]WANG J,ZHAO X,WANG Y,et al.circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma［J］.Cell Death & Disease,2020,11(1):32.
[4] WEHRHAN F,WEBER M,BARAN C,et al.PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood［J］.Journal of Cranio-maxillo-facial Surgery,2021,49(2):118-125.
[5] CONCHA-BENAVENTE F,KANSY B,MOSKOVITZ J,et al.PD-L1 mediates dysfunction in activated PD-1(+) NK cells in head and neck cancer patients［J］.Cancer Immunol Res,2018,6(12):1548-1560.
[6] VARI F,ARPON D,KEANE C,et al.Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL［J］.Blood,2018,131(16):1809-1819.
[7] BORST L,VAN DER BURG SH,VAN HALL T.The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment［J］.Clinical Cancer Research,2020,26(21):5549-5556.
[8] KAMIYA T,SEOW SV,WONG D,et al.Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells［J］.The Journal of Clinical Investigation,2019,129(5):2094-2106.
[9] CHEN Y,XIN Z,HUANG L,et al.CD8(+) T cells form the predominant subset of NKG2A(+) cells in human lung cancer［J］.Frontiers in Immunology,2019,10:3002.
[10] BEN YAHIA H,BOUJELBENE N,BABAY W,et al.Expression analysis of immune-regulatory molecules HLA-G,HLA-E and IDO in endometrial cancer［J］.Human Immunology,2020,81(6):305-313.
[11] RUGGERI L,URBANI E,ANDR P,et al.Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells［J］.Haematologica,2016,101(5):626-633.
[12] JACQUIER A,LAMBERT T,DELATTRE JF,et al.Tumor infiltrating and peripheral CD4(+)ILT2(+) T cells are a cytotoxic subset selectively inhibited by HLA-G in clear cell renal cell carcinoma patients［J］.Cancer Letters,2021,519:105-116.
[13] CHENG J,GAO X,ZHANG X,et al.Leukocyte immunoglobulin-like receptor subfamily B member 1 potentially acts as a diagnostic and prognostic target in certain subtypes of adenocarcinoma［J］.Medical Hypotheses,2020,144:109863.
[14] ZHANG Y,LU N,XUE Y,et al.Expression of immunoglobulin-like transcript (ILT)2 and ILT3 in human gastric cancer and its clinical significance［J］.Molecular Medicine Reports,2012,5(4):910-916.
[15] SUN YX,FENG Q,WANG SW,et al.HLA-G-ILT2 interaction contributes to suppression of bone marrow B cell proliferation in acquired aplastic anemia［J］.Annals of Hematology,2022,101(4):739-748.
[16] HARJUNP H,GUILLEREY C.TIGIT as an emerging immune checkpoint［J］.Clinical and Experimental Immunology,2020,200(2):108-119.
[17] YU X,HARDEN K,GONZALEZ LC,et al.The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells［J］.Nat Immunol,2009,10(1):48-57.
[18] STANIETSKY N,SIMIC H,ARAPOVIC J,et al.The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity［J］.Proceedings of the National Academy of Sciences of the United States of America,2009,106(42):17858-17863.
[19] CHAUVIN JM,KA M,PAGLIANO O,et al.IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-cell dysfunction in melanoma［J］.Clinical Cancer Research,2020,26(20):5520-5533.
[20] MAAS RJ,HOOGSTAD-VAN EVERT JS,VAN DER MEER JM,et al.TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer［J］.Oncoimmunology,2020,9(1):1843247.
[21] SUN H,HUANG Q,HUANG M,et al.Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma［J］.Hepatology,2019,70(1):168-183.
[22] DIXON KO,SCHORER M,NEVIN J,et al.Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity［J］.Journal of Immunology,2018,200(8):3000-3007.
[23] CHAN CJ,MARTINET L,GILFILLAN S,et al.The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions［J］.Nat Immunol,2014,15(5):431-438.
[24] JIN HS,PARK Y.Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy［J］.BMB Reports,2021,54(1):2-11.
[25] BLAKE SJ,STANNARD K,LIU J,et al.Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy［J］.Cancer Discovery,2016,6(4):446-459.
[26] MURUGESAN G,WEIGLE B,CROCKER PR.Siglec and anti-Siglec therapies［J］.Current Opinion in Chemical Biology,2021,62:34-42.
[27] DALY J,CARLSTEN M,O' DWYER M.Sugar free:novel immunotherapeutic approaches targeting siglecs and sialic acids to enhance natural killer cell cytotoxicity against cancer［J］.Frontiers in Immunology,2019,10:1047.
[28] JANDUS C,BOLIGAN KF,CHIJIOKE O,et al.Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance［J］.The Journal of Clinical Investigation,2014,124(4):1810-1820.
[29] STANCZAK MA,SIDDIQUI SS,TREFNY MP,et al.Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells［J］.The Journal of Clinical Investigation,2018,128(11):4912-4923.
[30] CAMPBELL KS,PURDY AK.Structure/function of human killer cell immunoglobulin-like receptors:lessons from polymorphisms,evolution,crystal structures and mutations［J］.Immunology,2011,132(3):315-325.
[31] DI VITO C,MIKULAK J,ZAGHI E,et al.NK cells to cure cancer［J］.Seminars in Immunology,2019,41:101272.
[32] SOLTANI S,MOSTAFAEI S,ASLANI S,et al.Association of KIR gene polymorphisms with type 1 diabetes:a meta-analysis［J］.Journal of Diabetes and Metabolic Disorders,2020,19(2):1777-1786.
[33] ZHANG C,LIU Y.Targeting NK cell checkpoint receptors or molecules for cancer immunotherapy［J］.Frontiers in Immunology,2020,11:1295.
[34] WANG Z,ZHU J,GU H,et al.The clinical significance of abnormal Tim-3 expression on NK cells from patients with gastric cancer［J］.Immunological Investigations,2015,44(6):578-589.
[35] XU L,HUANG Y,TAN L,et al.Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma［J］.International Immunopharmacology,2015,29(2):635-641.
[36] DA SILVA IP,GALLOIS A,JIMENEZ-BARANDA S,et al.Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade［J］.Cancer Immunol Res,2014,2(5):410-422.
[37] ACHARYA N,SABATOS-PEYTON C,ANDERSON AC.Tim-3 finds its place in the cancer immunotherapy landscape［J］.Journal for Immunotherapy of Cancer,2020,8(1):e000911.
[38] TAN S,XU Y,WANG Z,et al.Tim-3 hampers tumor surveillance of liver-resident and conventional NK cells by disrupting PI3K signaling［J］.Cancer Research,2020,80(5):1130-1142.
[39] SAKUISHI K,APETOH L,SULLIVAN JM,et al.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity［J］.The Journal of Experimental Medicine,2010,207(10):2187-2194.